Chairman, Chief Executive Officer, Chief Financial Officer and Director
Dr. Platt is a world-renown expert in carbohydrate chemistry and has founded three publicly-traded companies, creating nearly $1B for investors. He has lead two drug candidates from concept to human clinical trials. Prior to Boston Therapeutics, from 2001 to 2009, Dr. Platt was a Founder, Chief Executive Officer and Chairman of the Board at Pro-Pharmaceuticals, Inc., SafeScience, Inc. and International Gene Group, all publicly-traded companies.
Kenneth A. Tassey, Jr.,
President and Director
Mr. Tassey has served as president of Boston Therapeutics, Inc. since November 2010. Prior to that, Mr. Tassey co-founded Boston Therapeutics, Inc. and served as Chief Executive Officer and President since its inception in June 2009 and until its merger with Avanyx Therapeutics. From 2007 to 2009, Mr. Tassey was President of TKCI, a consulting firm for commercial finance projects. Prior to TKCI, from 2005 to 2007, Mr. Tassey served as President of Liberty Shore LLC, as a consultant to businesses and to commercial and residential lenders. Mr. Tassey has a background in business management and operations.
Jonathan B. Rome,
Chief Operating Officer
Mr. Rome was the Founder, President and Chief Executive Officer of ThePharmaNetwork, LLC, a New Jersey company focused on pharmaceutical portfolio development, licensing, sales, marketing and distribution of pharmaceuticals and active pharmaceutical ingredients, where he worked from 2000 to August 2012. Mr. Rome also was the Founder, President and Chief Executive Officer of Ascend Laboratories, LLC, a pharmaceutical business development, sales and marketing company, selling finished products under the Ascend label to all major U.S. customers and classes of trade, where he worked from 2000 to 2012. Mr. Rome has more than 30 years of experience in the pharmaceutical industry as an executive, entrepreneur and globally networked executive with experience throughout the global supply chain.
Director of Strategic Planning and Investor Relations
From 2007 to 2012, Mr. Squeglia served as Chief Financial Officer of Pro-Pharmaceuticals, Inc. (OTC: PRWP) and Galectin Therapeutics, Inc., (Nasdaq: GALT). From 2003 to 2007 Mr. Squeglia was Vice President of Investor Relations for Pro-Pharmaceuticals, Inc. and was instrumental in the Company’s listing on Amex, as well as in its fund-raising activities. From 2001 to 2003, Mr. Squeglia was a Partner in JFS Advisors, a management consulting firm that delivered strategic services to entrepreneurial businesses that included raising funds, business planning, positioning, branding, marketing and sales channel development. Previously, Mr. Squeglia helped to successfully launch an IPO for Summa Four, a telecommunications switching company and held senior management positions with Unisys, AT&T, ITT and Colonial Penn. Mr. Squeglia received an M.B.A. from Pepperdine University and a B.B.A. from The Wharton School, University of Pennsylvania.
Hana Chen-Walden, M.D,
Chief Medical Director (Consultant)
Dr. Chen-Walden is an Endocrinologist and has specialized in regulatory affairs in the pharmaceutical industry in the U.S and Europe. She has thirty years of regulatory experience with the EMEA and in individual European countries. Since 2004 until present, Dr. Chen-Walden consulted for European Clinical and Regulatory Consultancy in medical monitoring, quality assurance and regulatory input for clinical studies in the fields of oncology, cardiology, diabetes, neurology, respiratory diseases and medical devices. From 2000 – 2003, Dr. Chen-Walden was Director of International Regulatory Affairs Covalent Group Ltd. From 1997 – 2000 she was Medical, Drug Safety and Regulatory Director at CRC, a clinical CRO in France. Dr. Chen Walden received her Doctorate of Medicine from University of Tel Aviv, Israel. Dr. Chen-Walden has practiced medicine in Germany and France.
Dr. Peter Sheehan, M.D,
Advisor, Medical Director
Dr. Sheehan is an internationally respected specialist in the field of diabetes. Areas of clinical and research interest for Dr. Sheehan include peripheral artery disease, diabetic neuropathy, and wound healing. He has served as the American Diabetes Association (ADA) Foot Council Chairman, on the national Board of Directors, and currently as Chairman of the Cardiometabolic Risk Initiative. Dr. Sheehan was on the Board of Directors of the Wound Healing Society and served as President of the Wound Healing Foundation. He is also a member of the Steering Committee of the P.A.D. Coalition (peripheral artery disease). He is a graduate of the SUNY-Downstate School of Medicine, where he also completed his residency in Internal Medicine. Dr. Sheehan continued his training at the Yale University School of Medicine in New Haven where he completed a fellowship in Endocrinology and Metabolism.
David Liu, Ph.D,
Dr. Liu currently serves as Vice President, Research and Development at HDM Systems Corp. and manages the development of power electronic devices for battery-based systems used in transportation and green energy storage applications. In his previous work as a research scientist in the Biomedical Research Department at St. Elizabeth’s Medical Center, Tufts Medical School, Dr. Liu contributed to the fundamental understanding of the red blood cell membrane architecture, the molecular pathophysiology of various hereditary hemolytic anemia and identification of critical protein domains of red blood cell surface receptor for malaria invasion, He has published over sixty research papers on these subjects in a number of prestigious journals. He subsequently served as Chairman of the Board of International Power Devices, Inc. (IPD), a producer of high density DC/DC power supply devices used by telecommunication and data communication companies, such as Cisco and Nortel Networks; in January of 1999, Power-One acquired IPD for $48 million. Since 1992, Dr Liu has been an Associate Professor of Medicine, Tufts University School of Medicine, Boston, MA. Dr. Liu received his Ph.D. in Biochemistry from Carnegie-Mellon University.